Meeting
2022 ASCO Genitourinary Cancers Symposium
Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
Authors
Matt D. Galsky
Icahn School of Medicine at Mount Sinai, New York, NY
Matt D. Galsky , Dean F. Bajorin , J. Alfred Witjes , Jürgen E. Gschwend , Yoshihiko Tomita , Federico Nasroulah , Jun Li , Sandra Collette , Begoña Pérez-Valderrama , Marc-Oliver Grimm , Leonard Joseph Appleman , Gwenaelle Gravis , Andrea Necchi , Dingwei Ye , Frank Stenner , Megan Wind-Rotolo , Joshua Zhang , Keziban Unsal-Kacmaz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02632409
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 491)
DOI
10.1200/JCO.2022.40.6_suppl.491
Abstract #
491
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Prognostic significance of programmed death-ligand 1 (PD-L1) expression on tumor infiltrating immune cells (IC) in patients with stage IIIb colorectal cancer.
First Author: Shigehiro Koganemaru
Poster
2023 ASCO Breakthrough
Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.
First Author: Stephanie Pei Li Saw
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu
Poster
2023 ASCO Annual Meeting
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.
First Author: Junjie Li